BRISTOL-MYERS SQUIBB COMPANY Gain (Loss) on Extinguishment of Debt
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Gain (Loss) on Extinguishment of Debt of -$356.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for the quarter ending 2023-03-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for fiscal 2025 was -$356.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on extinguishment of debt for fiscal 2022 was -$266.00M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 3 month as first filed | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$356.00M 10-K · filed 2026-02-11 | |||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-11 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 10-Q · filed 2023-10-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-07-27 | $0.00 10-Q · filed 2023-07-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-04-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $9.00M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $9.00M derived: sum of 3 quarters · filed 2025-02-12 | -$266.00M 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-10-26 | $9.00M derived: sum of 2 quarters · filed 2023-10-26 | -$266.00M 10-Q · filed 2023-10-26 | -$266.00M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-06-30 | $9.00M 10-Q · filed 2023-07-27 | -$266.00M 10-Q · filed 2023-07-27 | -$266.00M derived: sum of 3 quarters · filed 2024-02-13 | -$266.00M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-03-31 | -$275.00M 10-Q · filed 2023-04-27 | -$275.00M derived: sum of 2 quarters · filed 2024-02-13 | -$275.00M derived: sum of 3 quarters · filed 2024-02-13 | -$275.00M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $0.00 derived: sum of 2 quarters · filed 2024-02-13 | $0.00 derived: sum of 3 quarters · filed 2024-02-13 | -$281.00M 10-K · filed 2024-02-13 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-10-26 | $0.00 derived: sum of 2 quarters · filed 2022-10-26 | -$281.00M 10-Q · filed 2022-10-26 | -$281.00M derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-07-27 | -$281.00M 10-Q · filed 2022-07-27 | -$281.00M derived: sum of 3 quarters · filed 2023-02-14 | -$281.00M derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-03-31 | -$281.00M 10-Q · filed 2022-04-29 | $281.00M 10-Q · filed 2021-04-29 | -$281.00M derived: sum of 2 quarters · filed 2023-02-14 | -$281.00M derived: sum of 3 quarters · filed 2023-02-14 | -$281.00M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $0.00 derived: sum of 2 quarters · filed 2023-02-14 | $0.00 derived: sum of 3 quarters · filed 2023-02-14 | $0.00 10-K · filed 2023-02-14 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-10-27 | $0.00 derived: sum of 2 quarters · filed 2021-10-27 | $0.00 10-Q · filed 2021-10-27 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-28 | $0.00 10-Q · filed 2021-07-28 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2021-04-29 | |||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-09 | |||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-24 | |||||
| 2018-06-30 | $0.00 10-Q · filed 2018-07-26 | $0.00 10-Q · filed 2018-07-26 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $0.00 derived: sum of 2 quarters · filed 2020-02-24 | -$109.00M derived: sum of 3 quarters · filed 2020-02-24 | -$109.00M 10-K · filed 2020-02-24 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | -$109.00M derived: sum of 2 quarters · filed 2018-10-25 | -$109.00M 10-Q · filed 2018-10-25 | |||
| 2017-06-30 | -$109.00M 10-Q · filed 2018-07-26 | -$109.00M 10-Q · filed 2018-07-26 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-25 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $0.00 derived: sum of 2 quarters · filed 2018-02-13 | -$180.00M derived: sum of 3 quarters · filed 2018-02-13 | -$180.00M 10-K · filed 2018-02-13 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | -$180.00M derived: sum of 2 quarters · filed 2016-10-27 | -$180.00M 10-Q · filed 2016-10-27 | |||
| 2015-06-30 | -$180.00M 10-Q · filed 2016-07-28 | -$180.00M 10-Q · filed 2016-07-28 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $0.00 derived: sum of 2 quarters · filed 2017-02-21 | -$45.00M 10-K · filed 2017-02-21 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | -$45.00M 10-Q · filed 2015-10-27 | ||||
| 2014-06-30 | -$45.00M 10-Q · filed 2015-07-23 | |||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$8.00M derived: sum of 2 quarters · filed 2015-02-13 | -$8.00M derived: sum of 3 quarters · filed 2015-02-13 | -$27.00M 10-K · filed 2015-02-13 | ||
| 2012-09-30 | -$8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-23 | -$8.00M derived: sum of 2 quarters · filed 2013-10-23 | -$27.00M 10-Q · filed 2013-10-23 | -$27.00M derived: sum of 4 quarters · filed 2014-02-14 | ||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$19.00M 10-Q · filed 2013-07-25 | -$19.00M derived: sum of 3 quarters · filed 2014-02-14 | -$19.00M derived: sum of 4 quarters · filed 2014-02-14 | ||
| 2012-03-31 | -$19.00M 10-Q · filed 2013-04-25 | -$19.00M derived: sum of 2 quarters · filed 2014-02-14 | -$19.00M derived: sum of 3 quarters · filed 2014-02-14 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $0.00 derived: sum of 2 quarters · filed 2014-02-14 | $10.00M 10-K · filed 2014-02-14 | |||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $10.00M 10-Q · filed 2012-10-24 | ||||
| 2011-06-30 | $10.00M 10-Q · filed 2012-07-25 | |||||
| 2010-12-31 | -$6.00M 10-K · filed 2013-02-15 | -$105.00M 10-K · filed 2011-02-18 | ||||
| 2009-12-31 | -$15.00M 10-K · filed 2011-02-18 | |||||
| 2008-12-31 | $26.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |